Fog­Phar­ma bags $145M, adds Alex­is Borisy to the board 

Fog­Phar­ma, a biotech from Har­vard re­searcher Greg Ver­dine that is led by for­mer John­son & John­son R&D leader Math­ai Mam­men, said it has raised $145 mil­lion in a Se­ries E fi­nanc­ing.

The nine-fig­ure round, biotech’s 13th of 2024, was led by Nex­tech In­vest and in­clud­ed par­tic­i­pa­tion from Alex Gorsky, Mam­men’s for­mer boss at J&J.

The Boston-area biotech is one of a few drug de­vel­op­ers to raise that many pri­vate rounds be­fore a move to the pub­lic mar­kets. The biotech last dis­closed a $178 mil­lion Se­ries D in No­vem­ber 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER